Crossmark

Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with chronic lung disease and pulmonary hypertension

Crossref DOI link: https://doi.org/10.1186/s12890-025-03538-8

Published Online: 2025-02-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gayen, Shameek

Pescatore, Jay

Bittner, Matthew

Naranjo, Mario

Criner, Gerard J.

Weaver, Sheila

,

D’Alonzo, Gilbert

Illipparambil, Lijo

Rali, Parth

Pourshahid, Seyedmohammad
License Information

Text and Data Mining valid from 2025-02-08

Version of Record valid from 2025-02-08
More Information

Article History

Received: 10 October 2024

Accepted: 29 January 2025

First Online: 8 February 2025

Declarations

:

: The study was approved by the local ethics committee of Temple University (IRB Protocol #31795). The need for patient consent to participate was waived by the Temple University IRB/ethics committee given the retrospective nature of the study. Procedures were followed in accordance with the ethical standards of the Western IRB and the Helsinki Declaration of 1975.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below